Treatment outcome in patients with stage III breast cancer treated with neoadjuvant chemotherapy

Takahashi,Ryuji; Toh,Uhi; Iwakuma,Nobutaka; Mishima,Mai; Fujii,Teruhiko; Takenaka,Miki; Koura,Keiko; Seki,Naoko; Kawahara,Akihiko; Kage,Mashayoshi; Ogo,Etsuyo; Shirouzu,Kazuo

doi:10.3892/etm.2013.1289

November 2013 Volume 6 Issue 5

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

November 2013 Volume 6 Issue 5

Full Size Image

Article

Treatment outcome in patients with stage III breast cancer treated with neoadjuvant chemotherapy

Authors:
- Ryuji Takahashi
- Uhi Toh
- Nobutaka Iwakuma
- Mai Mishima
- Teruhiko Fujii
- Miki Takenaka
- Keiko Koura
- Naoko Seki
- Akihiko Kawahara
- Mashayoshi Kage
- Etsuyo Ogo
- Kazuo Shirouzu
View Affiliations / Copyright

Affiliations: Department of Surgery, Kurume University School of Medicine, Kurume, Fukuoka 830-0011, Japan, Research Center for Innovative Cancer Therapy, Kurume University School of Medicine, Kurume, Fukuoka 830-0011, Japan, Department of Pathology, Kurume University School of Medicine, Kurume, Fukuoka 830-0011, Japan, Department of Radiology, Kurume University School of Medicine, Kurume, Fukuoka 830-0011, Japan
Pages: 1089-1095
|
Published online on: September 6, 2013

https://doi.org/10.3892/etm.2013.1289
Expand metrics +

Abstract

Despite the good responses of patients (pts) with stage III breast cancer to neoadjuvant chemotherapy (NAC), most eventually relapse and have a poor prognosis. We investigated the prognostic indicators in pts with stage III breast cancer treated with NAC, using epirubicin and/or docetaxel. A total of 22 women with stage III breast cancer underwent NAC between January 2005 and May 2011. The regimens of NAC comprised ED (epirubicin 60 mg/m2 and docetaxel 60 mg/m2) in 10 cases, FEC (fluorouracil 500 mg/m2, epirubicin 75-100 mg/m2 and cyclophosphamide 500 mg/m2) in 10 cases and EC (epirubicin 60 mg/m2 and cyclophosphamide 600 mg/m2) in two cases. Following four cycles of each regimen, a further four cycles of D (docetaxel 70 mg/m2) were undertaken in nine cases. Subsequent to the completion of NAC and surgery, we assessed the clinicopathological results and performed prognostic analyses. Statistical analyses concerning disease-free survival (DFS) or overall survival (OS) were conducted by a Cox proportional hazard model. The median survival time was 66 months and there were 12 distant metastases and two local recurrences. Multivariate analyses showed the number of metastatic axillary lymph nodes (ALNs) [hazard ratio (HR), 1.079; P=0.023] was correlated with DFS, while the Ki-67 labeling index (HR, 1.109; P=0.042) and the number of metastatic ALNs (HR, 1.087; P=0.023) were correlated with OS. In conclusion, even if pts with stage III breast cancer show good responses to NAC using epirubicin and/or docetaxel, the majority eventually relapse and have a poor prognosis. The Ki-67 labeling index and the number of involved ALNs are suggested as prognostic indicators in stage III breast cancer.

View Figures

View References

1.	American Cancer Society: Breast cancer survival rates by stage. http://www.cancer.org/cancer/breastcancer/detailedguide/breast-cancer-survival-by-stageuri. Accessed September 6, 2012.
2.	Bhargava R, Beriwal S, Dabbs DJ, Ozbek U, Soran A, Johnson RR, et al: Immunohistochemical surrogate markers of breast cancer molecular classes predicts response to neoadjuvant chemotherapy: a single institutional experience with 359 cases. Cancer. 116:1431–1439. 2010. View Article : Google Scholar
3.	Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Chollichio F, et al: The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 13:2329–2334. 2007. View Article : Google Scholar : PubMed/NCBI
4.	Chávez-MacGregor M and González-Angulo AM: Breast cancer, neoadjuvant chemotherapy and residual disease. Clin Transl Oncol. 12:461–467. 2010.
5.	Kong X, Moran MS, Zhang N, Haffy B and Yang Q: Meta-analysis confirms achieving pathological complete response after neoadjuvant chemotherapy predicts favourable prognosis for breast cancer patients. Eur J Cancer. 47:2084–2090. 2011. View Article : Google Scholar
6.	Zhang GC, Zhang YF, Xu FP, Qian XK, Guo ZB, Ren CY and Yao M: Axillary lymph node status, adjusted for pathologic complete response in breast and axilla after neoadjuvant chemotherapy, predicts differential disease-free survival in breast cancer. Curr Oncol. 20:e180–192. 2013. View Article : Google Scholar
7.	Kim J, Lee J, Chang E, Suh K, Lee C, Jee J and Shin H: Prognostic factors in patients with stage II/III breast cancer treated with adjuvant extension of neoadjuvant chemotherapy: a retrospective cohort study with ten-years of follow-up data. J Breast Cancer. 14:39–45. 2011.PubMed/NCBI
8.	Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar
9.	Kurosumi M, Akashi-Tanaka S, Akiyama F, Komoike Y, Mukai H, Nakamura S, et al Committee for Production of Histopathological Criteria for Assessment of Therapeutic Response of Japanese Breast Cancer Society: Histopathological criteria for assessment of therapeutic response in breast cancer (2007 version). Breast Cancer. 15:5–7. 2008. View Article : Google Scholar : PubMed/NCBI
10.	Tausch C, Taucher S, Dubsky P, Seifert M, Reitsamer R, Kwasny W, et al: Prognostic value of number of removed lymph nodes, number of involved lymph nodes, and lymph node ratio in 7502 breast cancer patients enrolled onto trials of the Austrian Breast and Colorectal Cancer Study Group (ABCSG). Ann Surg Oncol. 19:1808–1817. 2012. View Article : Google Scholar
11.	Ionta MT, Atzori F, Deidda MC, Pusceddu V, Palmeri S, Frau B, et al: Long-term outcomes in stage IIIB breast cancer patients who achieved less than a pathological complete responses (<pCR) after primary chemotherapy. Oncologist. 14:1051–1060. 2009.PubMed/NCBI
12.	Tanioka M, Shimizu C, Yonemori K, Yoshimura K, Tamura K, Kouno T, et al: Predictors of recurrence in breast cancer patients with a pathologic complete response after neoadjuvant chemotherapy. Br J Cancer. 103:297–302. 2010. View Article : Google Scholar : PubMed/NCBI
13.	Yuan Z, Qu X, Zhang ZT and Wang Y: Neoadjuvant chemotherapy in patients with stage II and III breast cancer. Chin Med J (Engl). 122:2993–2997. 2009.PubMed/NCBI
14.	Luporsi E, André F, Spyratos F, Martin PM, Jacqueimer J, Penault-Llorca F, et al: Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review. Breast Cancer Res Treat. 132:895–915. 2012. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Treatment outcome in patients with stage III breast cancer treated with neoadjuvant chemotherapy

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Related Articles